Description: Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.
Home Page: www.xencor.com
465 North Halstead Street
Pasadena,
CA
91107
United States
Phone:
626 305 5900
Officers
| Name | Title |
|---|---|
| Dr. Bassil I. Dahiyat Ph.D. | Co-Founder, CEO, President & Director |
| Dr. John R. Desjarlais Ph.D. | Executive VP of Research & Chief Scientific Officer |
| Ms. Celia E. Eckert J.D. | Senior VP, General Counsel & Corporate Secretary |
| Dr. Nancy Valente M.D. | Executive VP & Chief Development Officer |
| Mr. Bart Jan Cornelissen | Senior VP & CFO |
| Mr. Charles Liles | Associate Director and Head of Corporate Communications & Investor Relations |
| Ms. Jennifer Sandoz | Senior VIce President of Human Resources |
| Dr. Jeremy Grunstein Ph.D. | Senior Vice President of Business Development |
| Mr. Kirk Rosemark RAC | Senior Vice President of Regulatory Affairs & Quality Assurance |
| Mr. Eric P. Kowack | Senior Vice President of Program Leadership & Alliance Management |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.4152 |
| Price-to-Sales TTM: | 19.7928 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 280 |